Tuberculosis is a highly contagious disease caused by the Mycobacterium tuberculosis complex (MTBC). Although TB is treatable, multidrug-resistant, extensively drug-resistant, and totally drug-resistant forms of M. tuberculosis have become a new life-threatening concern. New anti-TB drugs that are capable of curing these drug-resistant strains are urgently needed. The purpose of this study is to determine the antimycobacterial activity of D-enantiomer human lactoferricin 1-11 (D-hLF 1-11) against mycobacteria in vitro using a 3-(4,5-dimethylthiazol-2-yl)-2,5-dephenyltetrazolium bromide colorimetric assay, resazurin microplate assay, and microscopic observation drug susceptibility assay. Three previously described antimicrobial peptides, protegrin-1, AK 15-6, and melittin, with potent anti-TB activity, were included in this study. The findings suggest that D-hLF 1-11 can inhibit the growth of M. tuberculosis with a minimum inhibitory concentration of 100–200 µg/mL in susceptible, isoniazid (INH)-monoresistant, rifampicin (RF)-monoresistant, and MDR strains. The peptide can also inhibit some nontuberculous mycobacteria and other MTBC in similar concentrations. The antibiofilm activity of D-hLF 1-11 against the biofilm-forming M. abscessus was determined by crystal violet staining, and no significant difference is observed between the treated and untreated biofilm control. The checkerboard assay was subsequently carried out with M. tuberculosis H37Rv and the results indicate that D-hLF 1-11 displays an additive effect when combined with INH and a synergistic effect when combined with RF, with fractional inhibitory concentration indices of 0.730 and 0.312, respectively. The red blood cell hemolytic assay was initially applied for the toxicity determination of D-hLF 1-11, and negligible hemolysis (<1%) was observed, despite a concentration of up to 4 mg/mL being evaluated. Overall, D-hLF 1-11 has potential as a novel antimycobacterial agent for the future treatment of drug-sensitive and drug-resistant M. tuberculosis infections.
Background: Despite the fact that the number of CT exams is small among all radiography investigations, a high amount of medical radiation exposure comes from CT application. Most developed nations have adopted regular audits to ensure optimization of ionizing radiations in the CT examinations, but on the contrary, it has infrequently been performed in developing countries like Nigeria. Objectives: This study was designed to carry out an audit of CT examinations at two selected diagnostic centers in the South-South region of Nigeria. Materials and methods: This study was a retrospective cross-sectional study conducted in two radiological facilities, which involved 210 tomographs of the chest, head, and abdomen, selected using a convenient method. The CT examinations were done using the departmental protocols and the generated data were analyzed statistically using descriptive statistics. Results: Head examination was the most commonly performed CT examination (56.7%), followed by abdominal 28.6 % and the least 14.8% was chest. The most common indication was a road traffic accident (RTA) 11.4%. The distribution of the type of CT machine that was used for the study showed that the Toshiba machine was used for most of the subjects 132 (62.9%) followed by Optima CT660 78 (37.1%). It was seen that 48.6% of the study used 0.75s, 40.5% used 0.5s, 10.5% used 0.35s and only 0.5% used 1s scan time. The effective doses were adult head (2.31±0.14), chest (4.65±0.21), abdominal (7.70±0.17), pediatric head (2.81±0.21), and pediatric chest (9.96±0.12). Conclusion: The carrying out of clinical audits is imperative to ensure both safeties of patients and diagnostic accuracy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.